Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 3 3Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 50NIH 5NETWORK 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × etoposide phosphate × Clear all
NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
340 enrolled
Lymphoid

Hodgkin Disease

NCT04924101 2025-07-23

KEYNOTE-B99

Merck Sharp & Dohme LLC

Phase 2 Completed
126 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT00191139 2010-02-17

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Completed
64 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡